Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase I trial with peptichemio.

L Israel, M Kohn, A Depierre

    Tumori
    |February 28, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Peptichemio, a novel chemotherapy, shows promise for patients with advanced cancers. Recommended doses for Phase II trials are 0.9 mg/kg twice weekly alone or 1.3 mg/kg once weekly with other agents.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Photoprotection from UV light-induced telomere shortening and DNA damage by a broad-spectrum sunscreen.

    Journal of photochemistry and photobiology. B, Biology·2026
    Same author

    Evaluation of the Efficacy of Photoprotective Formulations Applied in Conjunction With Topical Active Ingredients in Patients With Photodermatoses.

    Actas dermo-sifiliograficas·2026
    Same author

    Are workers protected? Analyzing sun protection policies in Andalusian municipalities.

    Public health·2025
    Same author

    Discussion Abounds on the Potential Carcinogenic Risks Associated With the Use of UV Curing Lamps for Permanent Nail Polish.

    Actas dermo-sifiliograficas·2024
    Same author

    Exposure to UV Radiation in Lifeguards on Barcelona's Beaches: An Underestimated Occupational Risk.

    Actas dermo-sifiliograficas·2024
    Same author

    Exposure to UV Radiation in Lifeguards on Barcelona's Beaches: An Underestimated Occupational Risk.

    Actas dermo-sifiliograficas·2023
    Same journal

    End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.

    Tumori·2026
    Same journal

    Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.

    Tumori·2026
    Same journal

    Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.

    Tumori·2026
    Same journal

    Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.

    Tumori·2026
    Same journal

    Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.

    Tumori·2026
    Same journal

    Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.

    Tumori·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Conventional cytostatic drug treatment often fails in patients with advanced tumor progression.
    • Identifying effective salvage therapies is crucial for improving patient outcomes.

    Purpose of the Study:

    • To determine the maximum tolerated dose (MTD) and recommended doses of peptichemio for Phase II trials.
    • To evaluate the safety and toxicity profile of peptichemio in patients with refractory malignancies.

    Main Methods:

    • A dose-escalation study was conducted in 32 patients with progressive tumors.
    • Peptichemio was administered at increasing doses to groups of 4 patients.
    • Safety assessments included hematological and general toxicity evaluations.

    Main Results:

    Related Experiment Videos

    • The maximum tolerated dose (MTD) of peptichemio was determined to be 1.2 mg/kg twice weekly with minimal toxicity.
    • Recommended doses for Phase II trials are 0.9 mg/kg twice weekly (alone) and 1.3 mg/kg once weekly (in combination).
    • Co-administration with heparin and hydrocortisone was utilized to mitigate local phlebosclerosis.

    Conclusions:

    • Peptichemio demonstrates a tolerable safety profile and establishes recommended dosing for further clinical investigation.
    • These findings support the potential of peptichemio as a salvage therapy for patients with advanced cancer.
    • Optimized dosing strategies are proposed for both monotherapy and combination regimens.